Why Technology Transfer Fails: The Project Management Blind Spot in API Scale-Up

Updated: 19 October 2026 — revised guidance references and project-management recommendations.

API technology transfer can fail even when a process performs well in the laboratory. Plant equipment, mixing, heat transfer, impurity behaviour and operating conditions may introduce technical risks. In an API technology transfer CDMO partnership, those risks can increase when responsibilities, knowledge transfer and readiness decisions are poorly coordinated.

Project management connects the technical work, quality responsibilities and commercial commitments. It helps the team expose gaps early and act on them; it does not replace scientific understanding or quality approval.

The handoff needs an accountable owner

R&D owns process knowledge. Manufacturing owns plant execution. Quality and Regulatory Affairs assess the implications within their responsibilities. The transfer plan needs a named coordinator and clear ownership of each deliverable so work does not disappear between these functions.

Define the sending and receiving teams, decision authorities, document owners, acceptance criteria and escalation route before committing to a transfer date.

Four gaps to check before scale-up

1. Documentation without usable process knowledge. A document package may omit the reasoning behind operating ranges, difficult steps, observed failure modes and troubleshooting decisions. The receiving team needs access to that knowledge and a route for resolving questions.

2. Knowledge concentrated in one person. Record structured discussions and practical learning so the transfer can proceed without depending on one scientist’s availability. Assign owners to unanswered questions and verify closure.

3. Equipment and scale differences without an assessment. Differences in mixing, heat removal, charging, filtration or drying may affect process performance. Plan technical assessment, appropriate studies and specialist review before deciding the receiving site is ready.

4. Handoffs without agreed acceptance criteria. The sender may consider a report complete while the receiving team still needs clarification, analytical readiness or training. Agree what each milestone means and what evidence supports completion.

What the project manager coordinates

Build an integrated transfer plan covering the applicable process package, analytical-method transfer, equipment assessment, materials, training, engineering work, qualification or validation activities, quality review and regulatory impact assessment.

For each deliverable, record its owner, predecessor, required-by date, forecast date and acceptance evidence. Review technical uncertainties and coordination risks together. Escalate decisions before they consume the time available for the next dependent activity.

A readiness review should distinguish completed evidence, open technical work, unresolved deviations and accepted actions. Quality and technical approval remain with the designated specialists. A green schedule indicator cannot substitute for readiness evidence.

Use quality-system guidance in the right context

FDA’s ICH Q10 Pharmaceutical Quality System guidance provides a lifecycle framework that includes technology transfer, with knowledge management and quality risk management as enablers. It supports treating process knowledge as an organisational asset across development and manufacturing.

FDA’s Q8, Q9 and Q10 implementation questions and answers also discuss sharing relevant development and implementation knowledge during transfer. These references provide quality-system context; the management checklist here is PMSoft’s practical recommendation, not a mandated FDA project template.

Why this matters in a CDMO partnership

Client and CDMO teams may use different schedules, document systems and approval routes. Agree the interface: who supplies each input, who accepts it, how changes are assessed and how unresolved questions affect committed dates.

If a key deliverable slips, show its effect on the receiving site’s readiness and the client milestone. Record a supported recovery plan or revise the forecast rather than keeping an unsupported date.

Questions for the next transfer review

Can the receiving team explain the process rationale? Have equipment and scale differences been assessed? Are analytical methods, materials and training ready for the next stage? Does every open item have an owner and a decision date?

A successful transfer needs technical understanding, quality oversight and coordinated execution. Institutionalisation means applying these checks consistently across projects—from Concept to Commercialization.

PMSoft Pharma helps teams map handoffs, clarify ownership and establish integrated project reviews. Discuss your technology-transfer workflow.